Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 Phenotypes and Emergency Department Visits Among Patients Receiving Opioid Treatment.

JAMA network open - 1 Jul 2025

Nahid Noor A, McDonough Caitrin W, Wei Yu-Jung Jenny, Gong Yan, Empey Philip E, Haddad Andrew, Fillingim Roger B, Johnson Julie A

Abstract excerpt

Importance: Cytochrome P450 2D6 (CYP2D6) bioactivates hydrocodone, tramadol, codeine, and oxycodone to active metabolites that primarily provide analgesic activity. Reduced CYP2D6 activity may be associated with poor pain control. Objective: To evaluate associations of impaired CYP2D6 activity based on genotype or CYP2D6 inhibitors, alone and together, with analgesic activity of CYP2D6-metabolized opioids among...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Analgesics, Opioid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP2D6 Inhibitors

Share to Emergency Service, Hospital

Share to Genotype

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 40720122
DOI: 10.1001/jamanetworkopen.2025.23543
PMCID: PMC12305384

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 Phenotypes and Emergency Department Visits Among Patients Receiving Opioid Treatment.PMID 40720122Read ↗

CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.Semantic proximity Read ↗

Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid AnalgesicsSemantic proximity Read ↗

CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice.Semantic proximity Read ↗

Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.Semantic proximity Read ↗

The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.Semantic proximity Read ↗

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)Semantic proximity Read ↗

The potential of CYP2D6 phenotyping to improve opioid dosing strategiesSemantic proximity Read ↗

The Role of Clinical Pharmacogenetics and Opioid Interactions in Optimizing Treatment in Clinical PracticeSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.Semantic proximity Read ↗

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective MetabolismSemantic proximity Read ↗

Reviewing pharmacogenetics to advance precision medicine for opioidsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.